Andrew W Hutcheon
Overview
Explore the profile of Andrew W Hutcheon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brown I, Shalli K, McDonald S, Moir S, Hutcheon A, Heys S, et al.
Breast Cancer Res
. 2004 Aug;
6(5):R601-7.
PMID: 15318941
Introduction: Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes...
12.
Semple S, Gilbert F, Redpath T, Staff R, Ahearn T, Welch A, et al.
Eur Radiol
. 2004 Aug;
14(11):2038-45.
PMID: 15316743
The objective of this study was to investigate the relationship between vascular and metabolic characteristics of breast tumours in vivo, using contrast-enhanced dynamic MRI and 2-[(18)F] fluoro-2-deoxy- d-glucose (FDG) PET...
13.
Semple S, Gilbert F, Redpath T, Ahearn T, Welch A, Hutcheon A, et al.
Lancet Oncol
. 2003 Dec;
4(12):759.
PMID: 14662432
No abstract available.
14.
Ogston K, Miller I, Payne S, Hutcheon A, Sarkar T, Smith I, et al.
Breast
. 2003 Dec;
12(5):320-7.
PMID: 14659147
The clinical and complete pathological response of a primary breast cancer to chemotherapy has been shown to be an important prognostic for survival. However, the majority of patients do not...
15.
Hutcheon A, Heys S, Sarkar T
Breast Cancer Res Treat
. 2003 Jul;
79 Suppl 1:S19-24.
PMID: 12868802
Neoadjuvant chemotherapy produces substantial increases in clinical response rates and rates of breast conserving therapy. Pathologic response rate, though generally low, is an important outcome as it is presumably associated...
16.
McIntosh S, Ogston K, Payne S, Miller I, Sarkar T, Hutcheon A, et al.
Am J Surg
. 2003 Jun;
185(6):525-31.
PMID: 12781879
Background: Primary chemotherapy is being given in the treatment of large and locally advanced breast cancers, but a major concern is local relapse after therapy. This paper has examined patients...
17.
Keith D, Walker M, Walker L, Heys S, Sarkar T, Hutcheon A, et al.
Plast Reconstr Surg
. 2003 Mar;
111(3):1051-6; discussion 1057-9.
PMID: 12621174
The aims of the present study were to identify the characteristics of a consecutive series of women with newly diagnosed breast cancer and to evaluate the perceived benefits and disadvantages...
18.
Heys S, Hutcheon A, Sarkar T, Ogston K, Miller I, Payne S, et al.
Clin Breast Cancer
. 2002 Nov;
3 Suppl 2:S69-74.
PMID: 12435290
Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given...
19.
Petty R, Gilbert F, Hutcheon A, Sarkar T, McNally O, Parkin D
Lancet Oncol
. 2002 Jul;
3(8):513.
PMID: 12147438
No abstract available.
20.
Smith I, Heys S, Hutcheon A, Miller I, Payne S, Gilbert F, et al.
J Clin Oncol
. 2002 Mar;
20(6):1456-66.
PMID: 11896092
Purpose: To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to...